Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Avalo Therapeutics (AVTX) Other Operating Expenses (2017 - 2024)

Avalo Therapeutics (AVTX) has disclosed Other Operating Expenses for 8 consecutive years, with -$1000.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Other Operating Expenses rose 99.86% year-over-year to -$1000.0, compared with a TTM value of $87000.0 through Sep 2025, down 99.72%, and an annual FY2024 reading of $27.3 million, up 425.43% over the prior year.
  • Other Operating Expenses was -$1000.0 for Q3 2025 at Avalo Therapeutics, down from $2000.0 in the prior quarter.
  • Across five years, Other Operating Expenses topped out at $27.5 million in Q1 2024 and bottomed at -$1.3 million in Q4 2021.
  • Average Other Operating Expenses over 5 years is $2.1 million, with a median of $539000.0 recorded in 2022.
  • Peak annual rise in Other Operating Expenses hit 4883.3% in 2024, while the deepest fall reached 390.24% in 2024.
  • Year by year, Other Operating Expenses stood at -$1.3 million in 2021, then skyrocketed by 148.9% to $620000.0 in 2022, then soared by 494.52% to $3.7 million in 2023, then crashed by 97.67% to $86000.0 in 2024, then tumbled by 101.16% to -$1000.0 in 2025.
  • Business Quant data shows Other Operating Expenses for AVTX at -$1000.0 in Q3 2025, $2000.0 in Q2 2025, and $86000.0 in Q4 2024.